[go: up one dir, main page]

WO2019028669A1 - Solvent-free method for preparing levetiracetam - Google Patents

Solvent-free method for preparing levetiracetam Download PDF

Info

Publication number
WO2019028669A1
WO2019028669A1 PCT/CN2017/096408 CN2017096408W WO2019028669A1 WO 2019028669 A1 WO2019028669 A1 WO 2019028669A1 CN 2017096408 W CN2017096408 W CN 2017096408W WO 2019028669 A1 WO2019028669 A1 WO 2019028669A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
reaction
oxo
dimethylbutyl
levetiracetam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/096408
Other languages
French (fr)
Chinese (zh)
Inventor
潘洪杰
张文灵
王鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Zhicheng Pharmaceutical Co Ltd
Original Assignee
Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Zhicheng Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Huahai Pharmaceutical Co Ltd, Zhejiang Huahai Zhicheng Pharmaceutical Co Ltd filed Critical Zhejiang Huahai Pharmaceutical Co Ltd
Priority to CN201780092609.8A priority Critical patent/CN110799494B/en
Priority to PCT/CN2017/096408 priority patent/WO2019028669A1/en
Publication of WO2019028669A1 publication Critical patent/WO2019028669A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention belongs to the technical field of drug synthesis, and in particular relates to a method for preparing levetiracetam without solvent.
  • Levetiracetam is a high-efficiency, broad-spectrum antiepileptic drug developed by UCB of Belgium. It is mainly used for the treatment of localized and secondary generalized epilepsy.
  • the chemical name is (S)- ⁇ -B. Keto-2-oxo-1-pyrrolidine acetamide.
  • the method of the present invention is less polluting to the environment.
  • the object of the present invention is achieved by the following technical solutions.
  • R in the formula (I) is a C 1 -C 6 alkyl group, wherein the C 1 -C 6 alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2 -methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3 - dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-eth
  • the molar ratio of liquid ammonia to the raw material (S)- ⁇ -ethyl-2-oxo-1-pyrrolidine acetate (I) is 1:1 to 100. : 1.
  • the molar ratio of liquid ammonia to the starting material (S)- ⁇ -ethyl-2-oxo-1-pyrrolidine acetate (I) is from 5:1 to 30:1, preferably from 5:1 to 20 : 1.
  • the temperature of the aminolysis reaction is -80 to 50 °C.
  • liquid ammonia is in a liquid state, and the liquid ammonia concentration in the reaction system is large, but when the temperature is low, the reaction rate is slow; under high temperature conditions, liquid ammonia exhibits a gaseous state, and the liquid ammonia concentration in the reaction system is low.
  • the temperature of the aminolysis reaction is -30 to 20 °C.
  • the reaction system pressure of the aminolysis reaction is 0.2 to 5.0 MPa.
  • the reaction system pressure is from 0.5 to 3.0 MPa, and the reaction time is from 24-96 hours.
  • the method of the present invention further includes the following post-treatment: after the end of the aminolysis reaction, the liquid ammonia is recovered to obtain a crude levetiracetam. It was recrystallized by adding an organic solvent to obtain levetiracetam.
  • the organic solvent used for recrystallization is selected from a mixture of one or more of C 1 -C 4 alcohols, ketones, esters, and ethers.
  • the above C 1 -C 4 alcohols are selected from the group consisting of methanol, ethanol, isopropanol or butanol; the ketones are selected from the group consisting of acetone, methyl ethyl ketone or methyl isobutyl ketone; the above esters are ethyl acetate; the above ethers It is methyl tert-butyl ether.
  • the organic solvent used for recrystallization is selected from one or a mixture of acetone, ethyl acetate or methyl isobutyl ketone.
  • the recrystallization temperature is -20 to 20 ° C, and the recrystallization temperature is preferably -5 to 5 °C.
  • the present invention has the following advantages:
  • the preparation method of levetiracetam of the invention avoids the use of a large amount of organic solvent, reduces the three wastes (waste water, waste gas and waste residue), reduces the cost, and has simple operation and high yield, and the obtained levetiracetam is obtained.
  • the HPLC purity and optical purity are high, and the HPLC purity and optical purity are both above 99.5%, which fully meets the requirements of industrial production.
  • Acetone 200 g was added to dissolve the solid, and the mixture was heated to reflux. Slowly cool to 0 ° C, heat crystallization for 2 to 4 hours, filter, and dry to obtain levetiracetam. The yield was 32.7 g, the yield was 96.0%, the HPLC purity was 99.8%, and the isomer: 0.07%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

涉及一种制备左乙拉西坦的方法,其特征在于,在无溶剂条件下,以(S)-α-乙基-2-氧代-1-吡咯烷乙酸酯为原料,通过与液氨进行氨解反应得到左乙拉西坦。所提供的方法三废低,收率和纯度好,符合工业化生产的要求。The invention relates to a method for preparing levetiracetam, which comprises (S)-α-ethyl-2-oxo-1-pyrrolidine acetate as a raw material and a liquid in the absence of a solvent. Ammonia is subjected to an aminolysis reaction to obtain levetiracetam. The method provided has low waste, good yield and purity, and meets the requirements of industrial production.

Description

一种无溶剂制备左乙拉西坦的方法Method for preparing levetiracetam without solvent 技术领域Technical field

本发明属于药物合成技术领域,具体涉及一种无溶剂制备左乙拉西坦的方法。The invention belongs to the technical field of drug synthesis, and in particular relates to a method for preparing levetiracetam without solvent.

背景技术Background technique

左乙拉西坦是由比利时UCB公司开发的一种高效的、毒副作用小的广谱抗癫痫药,主要用于治疗局限性及继发性全身癫痫,化学名为(S)-α-乙基-2-氧代-1-吡咯烷乙酰胺。Levetiracetam is a high-efficiency, broad-spectrum antiepileptic drug developed by UCB of Belgium. It is mainly used for the treatment of localized and secondary generalized epilepsy. The chemical name is (S)-α-B. Keto-2-oxo-1-pyrrolidine acetamide.

目前,国内外左乙拉西坦的制备方法有很多报道,主要采用化学拆分法。工业上常用的合成方法有以下两类:At present, there are many reports on the preparation methods of levetiracetam at home and abroad, mainly using chemical resolution. There are two types of synthetic methods commonly used in industry:

(1)比利时UCB公司开发的以消旋的(R/S)-α-乙基-2-氧代-1-吡咯烷乙酸为原料,(R)-α-甲基苄胺为拆分剂,在苯中拆分,再用碱处理,得到(S)-α-乙基-2-氧代-1-吡咯烷乙酸。(S)-α-乙基-2-氧代-1-吡咯烷乙酸与氯甲酸乙酯反应,再通过氨解得到左乙拉西坦。(1) The (R/S)-α-ethyl-2-oxo-1-pyrrolidineacetic acid was developed from UCB of Belgium, and (R)-α-methylbenzylamine was used as a resolving agent. It is resolved in benzene and treated with a base to give (S)-α-ethyl-2-oxo-1-pyrrolidineacetic acid. (S)-α-Ethyl-2-oxo-1-pyrrolidineacetic acid is reacted with ethyl chloroformate, and then left cilacetam is obtained by aminolysis.

Figure PCTCN2017096408-appb-000001
Figure PCTCN2017096408-appb-000001

(2)以2-氨基丁酰胺为原料,通过L-酒石酸拆分,氨气解离、氯化氢成盐得到(S)-2-氨基丁酰胺盐酸盐。(S)-2-氨基丁酰胺盐酸盐与4-氯丁酰氯反应,最后通过环合反应得到左乙拉西坦。 (2) Using 2-aminobutyramide as a raw material, it is resolved by L-tartaric acid, ammonia is dissociated, and hydrogen chloride is salted to obtain (S)-2-aminobutanamide hydrochloride. (S)-2-Aminobutyramide hydrochloride is reacted with 4-chlorobutyryl chloride, and finally left cilacetam is obtained by a ring closure reaction.

Figure PCTCN2017096408-appb-000002
Figure PCTCN2017096408-appb-000002

上述的合成路线均采用传统的化学拆分方法构建手性中心,工艺路线长,原子利用率低。同时化学拆分法中使用的溶剂和试剂对环境危害性大,三废(废水、废气和废渣)量大,在一定程度上限制了工业化应用。The above synthetic routes all use the traditional chemical separation method to construct the chiral center, the process route is long, and the atomic utilization rate is low. At the same time, the solvents and reagents used in the chemical decomposition method are harmful to the environment, and the large amount of the three wastes (waste water, waste gas and waste residue) limits the industrial application to a certain extent.

发明内容Summary of the invention

本发明的目的是提供一种新的无溶剂制备左乙拉西坦的方法。本发明的方法对环境污染小。本发明的目的是通过下列技术方案来实现的。It is an object of the present invention to provide a novel solventless process for the preparation of levetiracetam. The method of the present invention is less polluting to the environment. The object of the present invention is achieved by the following technical solutions.

一种制备左乙拉西坦的方法,其特征在于,在无溶剂条件下,以式(I)所示的(S)-α-乙基-2-氧代-1-吡咯烷乙酸酯为原料,通过与液氨进行氨解反应得到式(II)所示的左乙拉西坦,合成路线如下所示:A method for preparing levetiracetam characterized by (S)-α-ethyl-2-oxo-1-pyrrolidine acetate represented by formula (I) in the absence of a solvent As a raw material, the ampicillin shown by the formula (II) is obtained by aminolysis reaction with liquid ammonia, and the synthetic route is as follows:

Figure PCTCN2017096408-appb-000003
Figure PCTCN2017096408-appb-000003

式(I)中的R为C1~C6烷基,其中C1~C6烷基选自甲基、乙基、丙基、异丙基、丁基、1-甲基丙基、2-甲基丙基、1,1-二甲基乙基、戊基、1-甲基丁基、2-甲基丁基、3-甲基丁基、2,2-二甲基丙基、1-乙基丙基、己基、1,1-二甲基丙基、1,2-二甲基丙基、1-甲基戊基、2-甲基戊基、3-甲基戊基、4-甲基戊基、1,1-二甲基丁基、1,2-二甲基丁基、1,3-二甲基丁基、2,2-二甲基丁基、2,3-二甲基丁基、3,3-二甲基丁基、1-乙基丁基、2-乙基丁基、1,1,2-三甲基丙基、1,2,2-三甲基丙基、1-乙基-1-甲基丙基、1-乙基-2-甲基丙基、环丙基、环丁基、环戊基和环己 基,优选为甲基或乙基。R in the formula (I) is a C 1 -C 6 alkyl group, wherein the C 1 -C 6 alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2 -methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3 - dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-three Methylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, preferably methyl or ethyl base.

在上述的左乙拉西坦的合成方法中,液氨与原料(S)-α-乙基-2-氧代-1-吡咯烷乙酸酯(I)的摩尔比为1∶1~100∶1。优选地,液氨与原料(S)-α-乙基-2-氧代-1-吡咯烷乙酸酯(I)的摩尔比为5∶1~30∶1,优选为5∶1~20∶1。In the above synthesis method of levetiracetam, the molar ratio of liquid ammonia to the raw material (S)-α-ethyl-2-oxo-1-pyrrolidine acetate (I) is 1:1 to 100. : 1. Preferably, the molar ratio of liquid ammonia to the starting material (S)-α-ethyl-2-oxo-1-pyrrolidine acetate (I) is from 5:1 to 30:1, preferably from 5:1 to 20 : 1.

在上述的左乙拉西坦的合成方法中,所述的氨解反应的温度为-80~50℃。低温条件下,液氨呈现液体状态,反应体系液氨浓度大,但温度低时,反应速率慢;高温条件下,液氨呈现气体状态,反应体系液氨浓度低。优选地,氨解反应的温度为-30~20℃。In the above synthesis method of levetiracetam, the temperature of the aminolysis reaction is -80 to 50 °C. Under low temperature conditions, liquid ammonia is in a liquid state, and the liquid ammonia concentration in the reaction system is large, but when the temperature is low, the reaction rate is slow; under high temperature conditions, liquid ammonia exhibits a gaseous state, and the liquid ammonia concentration in the reaction system is low. Preferably, the temperature of the aminolysis reaction is -30 to 20 °C.

在上述的左乙拉西坦的合成方法中,所述氨解反应的反应体系压力为0.2~5.0MPa。反应体系压力越高,越有利于正向反应的进行,但反应体系压力过高时,氨解反应的异构化会加强。优选地,反应体系压力为0.5~3.0MPa,反应时间为24-96小时。In the above synthesis method of levetiracetam, the reaction system pressure of the aminolysis reaction is 0.2 to 5.0 MPa. The higher the pressure of the reaction system, the more favorable the forward reaction is, but when the pressure of the reaction system is too high, the isomerization of the aminolysis reaction is strengthened. Preferably, the reaction system pressure is from 0.5 to 3.0 MPa, and the reaction time is from 24-96 hours.

本发明的方法还包括以下后处理:氨解反应结束后,回收液氨,得到左乙拉西坦粗品。加入有机溶剂重结晶,得到左乙拉西坦。重结晶所用的有机溶剂选自C1~C4的醇类、酮类、酯类、醚类中的一种或几种的混合物。上述C1~C4的醇类选自甲醇、乙醇、异丙醇或丁醇;上述酮类选自丙酮、丁酮或甲基异丁基酮;上述酯类为乙酸乙酯;上述醚类为甲基叔丁基醚。优选地,重结晶所用的有机溶剂选自丙酮、乙酸乙酯或甲基异丁基酮中的一种或几种的混合物。所述的重结晶的温度为-20~20℃,重结晶的温度优选为-5~5℃。The method of the present invention further includes the following post-treatment: after the end of the aminolysis reaction, the liquid ammonia is recovered to obtain a crude levetiracetam. It was recrystallized by adding an organic solvent to obtain levetiracetam. The organic solvent used for recrystallization is selected from a mixture of one or more of C 1 -C 4 alcohols, ketones, esters, and ethers. The above C 1 -C 4 alcohols are selected from the group consisting of methanol, ethanol, isopropanol or butanol; the ketones are selected from the group consisting of acetone, methyl ethyl ketone or methyl isobutyl ketone; the above esters are ethyl acetate; the above ethers It is methyl tert-butyl ether. Preferably, the organic solvent used for recrystallization is selected from one or a mixture of acetone, ethyl acetate or methyl isobutyl ketone. The recrystallization temperature is -20 to 20 ° C, and the recrystallization temperature is preferably -5 to 5 °C.

与现有的技术相比,本发明具有以下优点:Compared with the prior art, the present invention has the following advantages:

本发明的左乙拉西坦的制备方法,避免了大量有机溶剂的使用,减少了三废(废水、废气和废渣),降低成本,同时操作简单,收率高,获得的左乙拉西坦的HPLC纯度和光学纯度高,HPLC纯度和光学纯度均达到99.5%以上,完全符合工业化生产的要求。The preparation method of levetiracetam of the invention avoids the use of a large amount of organic solvent, reduces the three wastes (waste water, waste gas and waste residue), reduces the cost, and has simple operation and high yield, and the obtained levetiracetam is obtained. The HPLC purity and optical purity are high, and the HPLC purity and optical purity are both above 99.5%, which fully meets the requirements of industrial production.

具体实施方式Detailed ways

下面结合实施例,对本发明的具体实施方式作进一步详细描述。以下实施例仅用于说明本发明,但不用于限制本发明的范围。 The specific embodiments of the present invention are further described in detail below with reference to the embodiments. The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.

实施例1Example 1

向高压反应釜中加入(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯(37g,0.20mol)并在搅拌下降温到-20℃,用减量法充注液氨(NH3)(68g,4.00mol)。关闭阀门,升温至15℃,在10~20℃的温度和0.5~2.0MPa的反应釜压力下进行氨解反应。反应40小时后,TLC检测无原料(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯剩余。氨解反应结束后,回收氨气,得到固体。加入丙酮(200g)来溶解固体,升温至回流溶清。缓慢降温至0℃,保温析晶2~4小时,过滤,烘干,得到左乙拉西坦。产量32.7g,收率96.0%,HPLC纯度99.8%,异构体:0.07%。Add (S)-α-ethyl-2-oxo-1-pyrrolidineacetic acid methyl ester (37 g, 0.20 mol) to the autoclave and cool to -20 ° C with stirring, and reduce the filling solution. Ammonia (NH 3 ) (68 g, 4.00 mol). The valve was closed, the temperature was raised to 15 ° C, and the aminolysis reaction was carried out at a temperature of 10 to 20 ° C and a reactor pressure of 0.5 to 2.0 MPa. After 40 hours of reaction, no residue of the starting material (S)-α-ethyl-2-oxo-1-pyrrolidineacetate was detected by TLC. After the completion of the aminolysis reaction, ammonia gas was recovered to obtain a solid. Acetone (200 g) was added to dissolve the solid, and the mixture was heated to reflux. Slowly cool to 0 ° C, heat crystallization for 2 to 4 hours, filter, and dry to obtain levetiracetam. The yield was 32.7 g, the yield was 96.0%, the HPLC purity was 99.8%, and the isomer: 0.07%.

实施例2Example 2

向高压反应釜中加入(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯(37g,0.20mol)并在搅拌下降温到-20℃,用减量法充注液氨(NH3)(68g,4.00mol)。关闭阀门,升温至25℃,在20~30℃的温度和0.5~2.0MPa的反应釜压力下进行氨解反应,反应32小时后,TLC检测无原料(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯剩余。氨解反应结束后,回收氨气,得到固体。。加入丙酮(200g)来溶解固体,升温至回流溶清。缓慢降温至0℃,保温析晶2~4小时,过滤,烘干,得到左乙拉西坦。产量31.8g,收率93.4%,HPLC纯度99.8%,异构体:0.08%。Add (S)-α-ethyl-2-oxo-1-pyrrolidineacetic acid methyl ester (37 g, 0.20 mol) to the autoclave and cool to -20 ° C with stirring, and reduce the filling solution. Ammonia (NH 3 ) (68 g, 4.00 mol). The valve was closed, the temperature was raised to 25 ° C, and the aminolysis reaction was carried out at a temperature of 20 to 30 ° C and a reactor pressure of 0.5 to 2.0 MPa. After the reaction for 32 hours, no raw material (S)-α-ethyl-2- was detected by TLC. Methyl oxo-1-pyrrolidine acetate remained. After the completion of the aminolysis reaction, ammonia gas was recovered to obtain a solid. . Acetone (200 g) was added to dissolve the solid, and the mixture was heated to reflux. Slowly cool to 0 ° C, heat crystallization for 2 to 4 hours, filter, and dry to obtain levetiracetam. The yield was 31.8 g, the yield was 93.4%, the HPLC purity was 99.8%, and the isomer: 0.08%.

实施例3Example 3

向高压反应釜中加入(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯(37g,0.20mol)并在搅拌下降温到-30℃,用减量法充注液氨(NH3)(102g,6.00mol)。关闭阀门,升温至0℃,在-5~5℃的温度和0.5~1.0MPa的反应釜压力下进行氨解反应,反应28小时后,TLC检测无原料(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯剩余。氨解反应结束后,回收氨气,得到固体。加入丙酮(200g)来溶解固体,升温至回流溶清。缓慢降温至0℃,保温析晶2~4小时。过滤,烘干,得到左乙拉西坦。产量32.9g,收率96.6%,HPLC纯度99.9%,异构体:0.05%。Add (S)-α-ethyl-2-oxo-1-pyrrolidineacetic acid methyl ester (37 g, 0.20 mol) to the autoclave and cool to -30 ° C with stirring, and reduce the filling solution. Ammonia (NH 3 ) (102 g, 6.00 mol). The valve was closed, the temperature was raised to 0 ° C, and the aminolysis reaction was carried out at a temperature of -5 to 5 ° C and a reactor pressure of 0.5 to 1.0 MPa. After 28 hours of reaction, no raw material (S)-α-ethyl-2 was detected by TLC. - Oxo-1-pyrrolidine acetate methyl ester remaining. After the completion of the aminolysis reaction, ammonia gas was recovered to obtain a solid. Acetone (200 g) was added to dissolve the solid, and the mixture was heated to reflux. Slowly cool to 0 ° C, and heat crystallization for 2 to 4 hours. Filter and dry to obtain levetiracetam. The yield was 32.9 g, the yield was 96.6%, the HPLC purity was 99.9%, and the isomer: 0.05%.

实施例4Example 4

向高压反应釜中加入(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯(37g, 0.20mol)并在搅拌下降温到0℃,用减量法充注液氨(NH3)(17g,2.00mol)。升温至10℃,在5~15℃的温度和1.0~3.0MPa的反应釜压力下进行氨解反应,反应72小时后,TLC检测无原料(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯剩余。氨解反应结束后,回收氨气,得到固体。加入丙酮(200g)来溶解固体,升温至回流溶清。缓慢降温至0℃,保温析晶2~4小时。过滤,烘干,得到左乙拉西坦。产量31.6g,收率92.8%,HPLC纯度99.7%,异构体:0.08%。Add (S)-α-ethyl-2-oxo-1-pyrrolidineacetic acid methyl ester (37 g, 0.20 mol) to the autoclave and cool to 0 °C with stirring, and fill the liquid ammonia with a reduction method. (NH 3 ) (17 g, 2.00 mol). The temperature was raised to 10 ° C, and the aminolysis reaction was carried out at a temperature of 5 to 15 ° C and a reactor pressure of 1.0 to 3.0 MPa. After 72 hours of reaction, no raw material (S)-α-ethyl-2-oxo was detected by TLC. Methyl 1-pyrrolidine acetate remained. After the completion of the aminolysis reaction, ammonia gas was recovered to obtain a solid. Acetone (200 g) was added to dissolve the solid, and the mixture was heated to reflux. Slowly cool to 0 ° C, and heat crystallization for 2 to 4 hours. Filter and dry to obtain levetiracetam. The yield was 31.6 g, the yield was 92.8%, the HPLC purity was 99.7%, and the isomer: 0.08%.

实施例5Example 5

向高压反应釜中加入(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯(37g,0.20mol)并在搅拌下降温到-20℃,用减量法充注液氨(NH3)(68g,4.00mol)。关闭阀门,升温至15℃,在10~20℃的温度和0.5~2.0MPa的反应釜压力下进行氨解反应,反应40小时后,TLC检测无原料(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯剩余。氨解反应结束后,回收氨气,得到固体。加入乙酸乙酯(200g)来溶解固体,升温至回流溶清。缓慢降温至0℃,保温析晶2~4小时。过滤,烘干,得到左乙拉西坦。产量31.8g,收率93.4%,HPLC纯度99.7%,异构体:0.07%。Add (S)-α-ethyl-2-oxo-1-pyrrolidineacetic acid methyl ester (37 g, 0.20 mol) to the autoclave and cool to -20 ° C with stirring, and reduce the filling solution. Ammonia (NH 3 ) (68 g, 4.00 mol). The valve was closed, the temperature was raised to 15 ° C, and the aminolysis reaction was carried out at a temperature of 10 to 20 ° C and a reactor pressure of 0.5 to 2.0 MPa. After 40 hours of reaction, no raw material (S)-α-ethyl-2- was detected by TLC. Methyl oxo-1-pyrrolidine acetate remained. After the completion of the aminolysis reaction, ammonia gas was recovered to obtain a solid. Ethyl acetate (200 g) was added to dissolve the solid, and the mixture was warmed to reflux. Slowly cool to 0 ° C, and heat crystallization for 2 to 4 hours. Filter and dry to obtain levetiracetam. The yield was 31.8 g, the yield was 93.4%, the HPLC purity was 99.7%, and the isomer: 0.07%.

实施例6Example 6

向高压反应釜中加入(S)-α-乙基-2-氧代-1-吡咯烷乙酸乙酯(40g,0.20mol)并在搅拌下降温到-20℃,用减量法充注液氨(NH3)(68g,4.00mol)。关闭阀门,升温至15℃,在10~20℃的温度和0.5~2.0MPa的反应釜压力下进行氨解反应,反应52小时后,TLC检测无原料(S)-α-乙基-2-氧代-1-吡咯烷乙酸甲酯剩余。氨解反应结束后,回收氨气,得到固体。。加入丙酮(200g)来溶解固体,升温至回流溶清。缓慢降温至0℃,保温析晶2~4小时。过滤,烘干,得到左乙拉西坦。产量32.5g,收率95.5%,HPLC纯度99.8%,异构体:0.08%。 To the autoclave, ethyl (S)-α-ethyl-2-oxo-1-pyrrolidine (40 g, 0.20 mol) was added and the temperature was lowered to -20 ° C under stirring, and the solution was filled with a reduced amount. Ammonia (NH 3 ) (68 g, 4.00 mol). The valve was closed, the temperature was raised to 15 ° C, and the aminolysis reaction was carried out at a temperature of 10 to 20 ° C and a reactor pressure of 0.5 to 2.0 MPa. After the reaction for 52 hours, no raw material (S)-α-ethyl-2- was detected by TLC. Methyl oxo-1-pyrrolidine acetate remained. After the completion of the aminolysis reaction, ammonia gas was recovered to obtain a solid. . Acetone (200 g) was added to dissolve the solid, and the mixture was heated to reflux. Slowly cool to 0 ° C, and heat crystallization for 2 to 4 hours. Filter and dry to obtain levetiracetam. The yield was 32.5 g, the yield was 95.5%, the HPLC purity was 99.8%, and the isomer: 0.08%.

Claims (7)

一种制备左乙拉西坦的方法,其特征在于,在无溶剂条件下,以式(I)所示的(S)-α-乙基-2-氧代-1-吡咯烷乙酸酯为原料,通过与液氨进行氨解反应得到式(II)所示的左乙拉西坦,合成路线如下所示:A method for preparing levetiracetam characterized by (S)-α-ethyl-2-oxo-1-pyrrolidine acetate represented by formula (I) in the absence of a solvent As a raw material, the ampicillin shown by the formula (II) is obtained by aminolysis reaction with liquid ammonia, and the synthetic route is as follows:
Figure PCTCN2017096408-appb-100001
Figure PCTCN2017096408-appb-100001
式(I)中的R为C1~C6烷基,其中C1~C6烷基选自甲基、乙基、丙基、异丙基、丁基、1-甲基丙基、2-甲基丙基、1,1-二甲基乙基、戊基、1-甲基丁基、2-甲基丁基、3-甲基丁基、2,2-二甲基丙基、1-乙基丙基、己基、1,1-二甲基丙基、1,2-二甲基丙基、1-甲基戊基、2-甲基戊基、3-甲基戊基、4-甲基戊基、1,1-二甲基丁基、1,2-二甲基丁基、1,3-二甲基丁基、2,2-二甲基丁基、2,3-二甲基丁基、3,3-二甲基丁基、1-乙基丁基、2-乙基丁基、1,1,2-三甲基丙基、1,2,2-三甲基丙基、1-乙基-1-甲基丙基、1-乙基-2-甲基丙基、环丙基、环丁基、环戊基和环己基,优选为甲基或乙基。。R in the formula (I) is a C 1 -C 6 alkyl group, wherein the C 1 -C 6 alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2 -methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3 - dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-three Methylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, preferably methyl or ethyl base. .
根据权利要求1所述的方法,所述液氨与(S)-α-乙基-2-氧代-1-吡咯烷乙酸酯的摩尔比为1∶1~100∶1。The method according to claim 1, wherein the molar ratio of liquid ammonia to (S)-α-ethyl-2-oxo-1-pyrrolidine acetate is from 1:1 to 100:1. 根据权利要求2所述的方法,所述液氨与(S)-α-乙基-2-氧代-1-吡咯烷乙酸酯的摩尔比为5∶1~30∶1,优选为5∶1~20∶1。The method according to claim 2, wherein the molar ratio of liquid ammonia to (S)-α-ethyl-2-oxo-1-pyrrolidine acetate is from 5:1 to 30:1, preferably 5 : 1 to 20:1. 根据权利要求1所述的方法,所述氨解反应的温度为-80~50℃。The method according to claim 1, wherein the temperature of the aminolysis reaction is -80 to 50 °C. 根据权利要求4所述的方法,所述氨解反应的温度为-30~20℃。The method according to claim 4, wherein the temperature of the aminolysis reaction is -30 to 20 °C. 根据权利要求1所述的方法,所述氨解反应的反应体系压力为0.2~5.0MPa。The method according to claim 1, wherein the reaction system pressure of the aminolysis reaction is 0.2 to 5.0 MPa. 根据权利要求6所述的方法,所述氨解反应的反应体系压力为0.5~3.0MPa。 The method according to claim 6, wherein the reaction system pressure of the aminolysis reaction is from 0.5 to 3.0 MPa.
PCT/CN2017/096408 2017-08-08 2017-08-08 Solvent-free method for preparing levetiracetam Ceased WO2019028669A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201780092609.8A CN110799494B (en) 2017-08-08 2017-08-08 Method for preparing levetiracetam without solvent
PCT/CN2017/096408 WO2019028669A1 (en) 2017-08-08 2017-08-08 Solvent-free method for preparing levetiracetam

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/096408 WO2019028669A1 (en) 2017-08-08 2017-08-08 Solvent-free method for preparing levetiracetam

Publications (1)

Publication Number Publication Date
WO2019028669A1 true WO2019028669A1 (en) 2019-02-14

Family

ID=65273316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/096408 Ceased WO2019028669A1 (en) 2017-08-08 2017-08-08 Solvent-free method for preparing levetiracetam

Country Status (2)

Country Link
CN (1) CN110799494B (en)
WO (1) WO2019028669A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095362A1 (en) * 2005-03-10 2006-09-14 Rubamin Limited Process for preparing levetiracetam
EP1419144B1 (en) * 2001-08-10 2008-10-08 UCB Pharma S.A. Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
CN101511786A (en) * 2006-07-25 2009-08-19 Zach系统股份公司 Process for the preparation of levetiracetam

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1419144B1 (en) * 2001-08-10 2008-10-08 UCB Pharma S.A. Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
WO2006095362A1 (en) * 2005-03-10 2006-09-14 Rubamin Limited Process for preparing levetiracetam
CN101511786A (en) * 2006-07-25 2009-08-19 Zach系统股份公司 Process for the preparation of levetiracetam

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU, YUEJIN ET AL.: "Synthesis of Levetiracetam and Its Derivatives", CHINESE JOURNAL OF NEW DRUGS, vol. 16, no. 11, 31 December 2007 (2007-12-31), pages 860 - 864, XP055577025 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof

Also Published As

Publication number Publication date
CN110799494A (en) 2020-02-14
CN110799494B (en) 2023-06-06

Similar Documents

Publication Publication Date Title
US11639326B2 (en) Continuous flow synthesis of ibuprofen
US8242311B2 (en) Process for preparing 2,2-difluoroethylamine and salts thereof proceeding from difluoroacetonitrile
WO2019028669A1 (en) Solvent-free method for preparing levetiracetam
WO2017211129A1 (en) Method for manufacturing ephedrine or pseudoephedrine and ephedrine or pseudoephedrine intermediate
JP5531120B1 (en) Method for producing dodecacarbonyltriruthenium
JP6028606B2 (en) Method for producing amine compound
CN111499492A (en) A kind of preparation method of 2,2-difluoroethanol
CN108164423B (en) Preparation method of naftifine hydrochloride
TW201130785A (en) Process for preparing 2,2-difluoroethylamine by hydrogenating 1,1-difluoro-2-nitroethane
CN117285411A (en) Preparation method of 2' -bromo-o-fluoro acetophenone
CN103588599A (en) Method for preparing hydroxylamine through nitro-reduction
CN114276209A (en) Process for continuously producing 6, 6-dimethyl-4-alkyne-2-alkene chloro heptane
AU2009356897A1 (en) Process for the preparation of O-desmethyl-venlafaxine and salts thereof
EP2699538B1 (en) Process for the preparation of alkyldiamines
CN115073298B (en) Method for synthesizing 2-methyl-3-trifluoromethylaniline using continuous flow microreactor
CN106631690A (en) Preparation method of 1-adamantanol
CN113493385B (en) Method for synthesizing butenafine hydrochloride
CN113493388B (en) Synthesis method of butenafine hydrochloride
CN111302962A (en) Rapid method for reducing nitro in aliphatic nitro compound into amino
CN115368236B (en) A method for preparing ethyl difluoroacetate
CN111635321B (en) Fluorinating agent and synthesis method thereof
JP5397706B2 (en) Method for producing high purity 1-benzyl-3-aminopyrrolidine
CN101445476A (en) Chemosynthesis method for Alpha-ethyl-2-oxo-1-methyl pyrrolidineacetate
JP5117185B2 (en) Method for producing optically active fluoroproline derivative
JP2021502351A (en) Continuous production method of 2,3-butanediol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17921052

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17921052

Country of ref document: EP

Kind code of ref document: A1